



SHILPA MEDICARE LIMITED

Regd. Office: # 10/80, First Floor, Rajendra Gunj, Raichur-584102(Karnataka)

AUDITED FINANCIAL RESULTS FOR 4TH QUARTER AND YEAR ENDED 31ST MARCH-2013

(Rs. In lacs)

PART-I

	Particulars	Quarter Ended						Year ended			
		Standalone			Consolidated			Standalone		Consolidated	
		Audited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited	Audited S	Audited	Audited S
		31.03.13	31.12.12	31.03.12	31.03.13	31.12.12	31.03.12	31.03.13	31.03.12	31.03.13	31.03.12
1	Income from operations										
	(a) Net sales/income from operations (Net of Excise Duty)	8687.50	8396.11	8187.23	9852.40	9404.02	9484.34	32819.59	27975.94	37132.34	31818.19
	(b) Other operating income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total income from operations (net)	8687.50	8396.11	8187.23	9852.40	9404.02	9484.34	32819.59	27975.94	37132.34	31818.19
2	Expenses										
	(a) Cost of materials consumed	5075.54	4418.34	4894.32	5357.76	4612.21	5144.30	19909.50	18638.99	20904.52	19679.20
	(b) Purchases of stock-in-trade	41.51	16.69	20.15	41.51	16.69	85.00	263.10	562.72	263.10	562.72
	(c) Changes in inventories of finished goods, WIP, Stock in	352.95	886.87	332.42	415.84	770.04	334.22	370.77	-1701.17	318.99	-1845.00
	(d) Employee benefits expense	647.57	689.06	528.25	1222.10	1164.72	992.24	2559.86	1951.07	4551.27	3630.31
	(e) Depreciation and amortisation expense	323.58	325.75	291.72	337.65	407.80	361.67	1275.36	1143.85	1533.99	1436.24
	(f) Other expenses	794.24	954.09	574.19	1113.27	1160.46	832.31	3234.20	2943.39	4207.68	3727.40
	Total Expense	7235.39	7290.80	6641.05	8488.13	8131.92	7749.74	27612.79	23538.85	31779.55	27190.87
3	Profit/(Loss) from Operations before Other Income, Finance Costs & exceptional items (1-2)	1452.11	1105.31	1546.18	1364.27	1272.10	1734.60	5206.80	4437.09	5352.79	4627.32
4	Other Income	130.83	73.03	240.74	163.56	62.27	202.38	500.64	778.60	501.05	828.16
5	Profit/(Loss) from Ordinary activities before finance cost & exceptional items (3+/-4)	1582.94	1178.34	1786.92	1527.83	1334.37	1936.98	5707.44	5215.69	5853.84	5455.48
6	Finance costs	30.06	37.28	35.15	31.57	40.08	43.85	135.94	149.20	143.60	167.41
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5 +/- 6)	1552.88	1141.06	1751.77	1496.26	1294.29	1893.13	5571.50	5066.49	5710.24	5288.07
8	Exceptional items	0.00	0.00	0.00			0.00	0.00	0.00	0.00	0.00
9	Profit/(Loss) from Ordinary Activities before tax (7 +/- 8)	1552.88	1141.06	1751.77	1496.26	1294.29	1893.13	5571.50	5066.49	5710.24	5288.07
10	Tax expense	230.16	42.99	172.33	220.43	29.77	222.14	965.18	1154.45	953.08	1222.44
11	Net Profit/(Loss) from ordinary activities after tax (9 +/-10)	1322.72	1098.07	1579.44	1275.83	1264.52	1670.99	4606.32	3912.04	4757.16	4065.63
12	Extraordinary Items Income / (Expenses)	-10.37	0.00	62.72	-10.37	0.00	62.72	-10.37	62.72	-10.37	62.72
13	Net Profit/(Loss) for the period (11+12)	1312.35	1098.07	1642.16	1265.46	1264.52	1733.71	4595.95	3974.76	4746.79	4128.35
14	Share of Profit / (Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Add:(Gain)/ loss pertaining to Minority Interest	0.00	0.00	0.00	-14.56	9.71	8.62	0.00	0.00	-12.32	12.46
16	Net Profit / (loss) after taxes, minority interest and share of profit/(loss) of associates (13+/-14+/-15)	1312.35	1098.07	1642.16	1250.90	1274.23	1742.33	4595.95	3974.76	4734.47	4140.81
17	Paid-up equity share capital (Face value of Rs 2/-)	490.48	490.48	490.48	490.48	490.48	490.48	490.48	490.48	490.48	490.48
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	32588.13	28239.44	31551.98	27107.11
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.2/- each) (not annualized):										
	a) Basic	5.39	4.48	6.66	5.10	5.20	7.04	18.78	16.27	19.40	16.89
	b) Diluted	5.39	4.48	6.66	5.10	5.20	7.04	18.78	16.27	19.40	16.89
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.2/- each) (not annualized):										
	a) Basic	5.35	4.48	6.83	5.10	5.20	7.25	18.74	16.54	19.36	17.16
	b) Diluted	5.35	4.48	6.83	5.10	5.20	7.21	18.74	16.54	19.36	17.16



PART-II											
A.	PARTICULARS OF SHARE HOLDING										
1	Public Shareholding										
	- Number of Shares	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724
	- Percentage of shareholding	44.12	44.12	45.04	44.12	44.12	45.04	44.12	45.04	44.12	45.04
2	Promoters & Promoters group Shareholding										
	a) Pledged / Encumbered										
	- Number of shares	0	0	0	0	0	0	0	0	0	0
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	-	-	-	-	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-	-	-	-	-
	b) Non encumbered										
	- Number of shares	13704441	13704441	13204441	13704441	13704441	13204441	13704441	13204441	13704441	13204441
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.88	55.88	54.96	55.88	55.88	54.96	55.88	54.96	55.88	54.96
B	PARTICULARS OF INVESTOR COMPLAINTS										
	Particulars	Three Months ended 31 st March,2013									
	Pending at the beginning of the quarter	Nil									
	Received during the quarter	11									
	Disposed off during the quarter	11									
	Remaining unresolved at the end of the quarter	Nil									

Notes:

- The Audited Financial Results have been reviewed by the Audit Committee and approved at the meeting of the Board of Directors.
- Figures of the previous year/quarter have been regrouped/rearranged wherever necessary.
- As per AS-17 reportable segment is only one i.e Bulk Drug & API, therefore, segment reporting is not applicable.
- The figures of last quarter of current year are the balancing figures between audited figures for the full financial year and unaudited published year-to-date figures for nine months ended.
- Option given vide MCA's notification dt. 29.12.2011 on the Accounting Standard 11, "The effects of changes in Foreign Exchange Rates" is exercised by the Company. Accordingly, the Exchange Fluctuation impact on Fixed Assets acquired from External Commercial Borrowings is Capitalized and Exchange Fluctuation on investment in Foreign Currency is routed through "Foreign Currency Monetary Item Translation Difference Account".
- Tax Expenses includes Current Tax and Deferred Tax.
- Mat Credit of Rs 556.40 Lakhs has been recognized as at 31.03.2013, since the company is liable to pay tax under section.115JB of the Income Tax Act 1961.
- The Board of Director of the Company have recommended dividend of Rs 1.30 per share (i.e 65%) of face value of 2/- each, subject to approval in ensuing Annual General Meeting.
- Capital Advances includes a sum of Rs.37,364,888/- paid to ISO Tech Design, Canada by the Company towards supply of machinery for its Formulation project at Jadcherla. Due to inordinate delay by vendor, the Company has terminated its order and has filed a law suit for recovery of advance alongwith interest and damages with the local courts in Canada. The preliminary hearing proceeding are under process. As the outcome of the case cannot be determined at present the Company has not made any provision.
- \$ Standalone & Consolidated Audited figures for the previous year ended 31.03.2012 includes figures of Raichem Lifesciences pvt ltd which was merged with the Company w,e,f 01.04.2011 as per the order of Hon, High Court of Andhra Pradesh.






STANDALONE/CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 31st MARCH 2013
(Rs. In lacs)

Particulars	Standalone		Consolidated	
	31.03.2013	31.03.2012	31.03.2013	31.03.2012
	Audited	Audited	Audited	Audited
A. EQUITY AND LIABILITIES				
1. Shareholder's funds				
(a) Share Capital	490.48	490.48	490.48	490.48
(b) Reserves and Surplus	32588.13	28239.44	31551.98	27107.11
Sub.total-Shareholder's funds	33078.61	28729.92	32042.46	27597.59
2. Minority Interest	0.00	0.00	872.14	485.74
3. Non-Current Liabilities				
(a) Long-term borrowings	4321.86	507.49	7046.55	507.49
(b) Deferred tax liabilities (net)	2063.02	1910.77	2092.21	1971.13
(c) Other Long term liabilities	0.00	0.00	692.30	634.17
(d) Long-term provisions	31.24	75.83	19.51	0.00
Sub.total-Non-current liabilities	6416.12	2494.09	9850.57	3112.79
4. Current Liabilities				
(a) Short-term borrowings	3892.33	3573.15	4506.59	4124.28
(b) Trade payables	4884.84	5313.46	5237.20	5672.17
(c) Other current liabilities	2039.73	1827.68	2227.08	2033.81
(d) Short-term provisions	379.99	260.00	406.06	283.31
Sub.total-Current liabilities	11196.89	10974.29	12376.93	12113.57
TOTAL-EQUITY AND LIABILITIES	50691.62	42198.30	55142.10	43309.69
B. ASSETS				
1. Non-current Assets				
(a) Goodwill on Consolidation	0.00	0.00	523.46	518.10
(b) Fixed assets (Net Block)				
(i) Tangible /Intangible assets	15255.58	14084.14	17543.56	16142.80
(ii) Capital work-in-progress	11427.15	5526.53	12915.35	5771.24
	26682.73	19610.67	30982.37	22432.14
(c) Non current investments	3700.73	3311.29	14.12	11.47
(d) Long-term loans and advances	2039.07	1752.03	2921.64	2079.58
(e) Other non-current assets	0.00	0.00	25.15	0.00
Sub.total-Non-current assets	32422.53	24673.99	33943.28	24523.19
2. Current Assets				
(a) Current investments	5028.16	6802.17	5028.17	6802.17
(b) Inventories	6612.96	5986.95	7433.24	6732.02
(c) Trade receivables	3187.68	3318.70	4178.79	4052.67
(d) Cash and cash equivalents	1052.55	194.90	3043.27	227.21
(e) Short-term loans and advances	2309.27	1166.51	1358.44	842.29
(f) Other current assets	78.47	55.08	156.91	130.14
Sub.total-Current assets	18269.09	17524.31	21198.82	18786.50
TOTAL-ASSETS	50691.62	42198.30	55142.10	43309.69

Place:Hyderabad
Date: 29.05.2013



By the order of the Board of Directors
for SHILPA MEDICARE LIMITED


Omprakash Inani
Chairman